- Sep 21, 2017 – Alligator Bioscience to present ADC-1013 intratumoral clinical phase I study results at SITC in November 2017
- Sep 13, 2017 – Alligator Bioscience signs immunotherapy research collaboration agreement for 4-1BB
- Aug 23, 2017 – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) Interim report January – June 2017
“We have advanced our project pipeline significantly during the second quarter. The immuno-oncology antibody ATOR-1017 moved into pre-clinical development, and in addition, Alligator increased its focus on the co-stimulatory receptor 4-1BB with a co-development partnership agreement with Aptevo Therapeutics Inc. on the bispecific antibody ALG.APV-527. Our pipeline is now stronger than ever with four candidates for tumor-directed immunotherapy in clinical and pre-clinical development” said Per Norlén, CEO.